You are viewing: US Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The US Leukapheresis Market was valued at $25.56 Million in 2026 and projected to reach to $39.05 Million by 2031, representing a compound annual growth rate of 8.8%. The US leukapheresis market is poised for sustained growth through 2031, driven by the rising prevalence of hematologic malignancies and the expanding use of cell-based immunotherapies.

US Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Leukapheresis Market Trends and Insights

  • This expansion in the US reflects increasing adoption of leukapheresis procedures driven by rising incidence of hematologic malignancies and growing demand for cell-based therapies.
  • The US market benefits from advanced healthcare infrastructure, strong reimbursement frameworks, and significant investment in CAR-T cell therapy development. In the US, leukapheresis demand is fueled by the expanding patient population requiring apheresis procedures for both therapeutic and diagnostic purposes.
  • The US healthcare system's emphasis on precision medicine and personalized treatment approaches continues to drive market growth through 2031.
  • Additionally, the US market is characterized by technological innovations in apheresis equipment and increasing clinical applications beyond traditional oncology settings..

Key Market Statistics

  • CAGR (2026-2031) 8.8% CAGR
  • Market Size, 2026 ~USD 25.56 Million
  • Forecast, 2031 ~USD 39.05 Million
  • Country US

US Leukapheresis Market Overview

Market Size & Growth :

The US leukapheresis market is valued at $25.56 million in 2026 and is projected to reach $39.05 million by 2031, with a steady CAGR of 8.8%, outpacing many other medical device segments.

Rising Hematologic Malignancies :

Increasing incidence of blood cancers and leukemia in the US population is driving demand for leukapheresis procedures as a critical therapeutic intervention for patient management.

Cell-Based Therapy Expansion :

Growing adoption of CAR-T cell therapies and other advanced cell-based treatments in US hospitals and cancer centers is significantly boosting leukapheresis procedure volumes.

Advanced Healthcare Infrastructure :

The US benefits from state-of-the-art medical facilities, high healthcare spending, and strong reimbursement policies that support widespread adoption of leukapheresis technologies.

US Leukapheresis Market Dynamics

  • Healthcare providers across the US are increasingly investing in apheresis equipment and trained personnel to meet growing patient demand.
  • Favorable reimbursement landscapes and FDA approvals for novel cell therapies continue to create favorable conditions for market expansion.
  • The integration of leukapheresis into standard treatment protocols for leukemia and lymphoma management further strengthens market fundamentals.
  • Additionally, technological advancements in automated apheresis systems are improving procedure efficiency and patient outcomes, encouraging broader adoption across US medical centers..

Related Ecosystem

Key Takeaways

  • The US leukapheresis market is valued at $25.56 million in 2026 and will reach $39.05 million by 2031 at an 8.8% CAGR.
  • The US market is driven by rising CAR-T cell therapy adoption and increasing hematologic malignancy prevalence.
  • Advanced US healthcare infrastructure and favorable reimbursement policies support sustained market expansion.
  • Technological innovations in apheresis equipment are expanding clinical applications across the US healthcare system.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

US Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Manufacturers of apheresis equipment and leukapheresis systems need US market data to guide R&D investments, pricing strategies, and distribution channel development in America's high-value healthcare market.
  • Healthcare Providers & Hospitals : US hospital networks and cancer centers require market insights to justify capital expenditures on leukapheresis equipment, plan capacity expansion, and align procurement with growing patient demand.
  • Pharmaceutical & Biotech Companies : Cell therapy and immunotherapy developers need US leukapheresis market data to understand treatment adoption rates, identify partnership opportunities, and forecast commercial potential for CAR-T and similar therapies.
  • Investment & Private Equity Firms : Investors evaluating opportunities in US healthcare and medical technology require detailed market forecasts to assess portfolio companies, identify acquisition targets, and evaluate sector growth potential.
  • Healthcare Consultants & Analysts : Consulting firms and market research professionals need US-specific leukapheresis data to support client advisory work, competitive analysis, and strategic planning across the American healthcare landscape.

Key Companies in the US Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Precise US Market Sizing : Access validated market size data specific to the United States ($25.56M in 2026), enabling accurate financial planning and investment decisions for US-focused strategies.
  • Growth Trajectory Insights : Understand the 8.8% CAGR trajectory through 2031 to identify optimal market entry points and expansion opportunities within the US leukapheresis sector.
  • US-Specific Drivers & Trends : Gain detailed intelligence on US-driven factors including rising hematologic malignancy rates, CAR-T adoption, and reimbursement dynamics that directly impact market growth.
  • Competitive Positioning : Benchmark your US operations against market growth rates and identify gaps in the American market to develop targeted competitive strategies and product offerings.
  • Regulatory & Reimbursement Context : Leverage US-specific insights on FDA approvals, insurance coverage, and healthcare infrastructure to navigate regulatory pathways and optimize market penetration strategies.

Frequently asked questions

What is the current size of the US leukapheresis market?

The US leukapheresis market is estimated at $25.56 million in 2026.

What is the projected size of the US leukapheresis market by 2031?

The US leukapheresis market is projected to reach $39.05 million by 2031.

What is the growth rate of the US leukapheresis market?

The US leukapheresis market is expected to grow at a compound annual growth rate of 8.8% from 2026 to 2031.

What are the primary drivers of growth in the US leukapheresis market?

The US market growth is driven by increasing CAR-T cell therapy adoption, rising hematologic malignancy incidence, advanced healthcare infrastructure, and favorable reimbursement policies.

Which factors support the expansion of leukapheresis procedures in the US?

The US market expansion is supported by technological innovations in apheresis equipment, growing clinical applications, precision medicine adoption, and increased investment in cell-based therapies.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status